Boston Partners Raises Stock Holdings in GE HealthCare Technologies Inc. $GEHC

Boston Partners boosted its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 21.7% in the fourth quarter, HoldingsChannel reports. The firm owned 4,659,562 shares of the company’s stock after purchasing an additional 830,626 shares during the period. Boston Partners’ holdings in GE HealthCare Technologies were worth $382,223,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GEHC. Caitong International Asset Management Co. Ltd bought a new position in GE HealthCare Technologies during the 4th quarter worth approximately $34,000. Y Intercept Hong Kong Ltd lifted its holdings in GE HealthCare Technologies by 707.6% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 124,056 shares of the company’s stock worth $10,175,000 after buying an additional 108,695 shares during the last quarter. Wealthspire Advisors LLC lifted its holdings in GE HealthCare Technologies by 48.8% during the 4th quarter. Wealthspire Advisors LLC now owns 9,851 shares of the company’s stock worth $808,000 after buying an additional 3,230 shares during the last quarter. Macquarie Group Ltd. lifted its holdings in GE HealthCare Technologies by 16.7% during the 4th quarter. Macquarie Group Ltd. now owns 90,681 shares of the company’s stock worth $7,437,000 after buying an additional 12,974 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in GE HealthCare Technologies by 1.1% during the 4th quarter. Quadrant Capital Group LLC now owns 12,557 shares of the company’s stock worth $1,030,000 after buying an additional 140 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Transactions at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Peter J. Arduini bought 4,169 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were purchased at an average cost of $59.92 per share, for a total transaction of $249,806.48. Following the transaction, the chief executive officer directly owned 259,424 shares in the company, valued at $15,544,686.08. The trade was a 1.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kevin Lobo bought 10,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was acquired at an average price of $64.18 per share, for a total transaction of $641,800.00. Following the completion of the transaction, the director owned 14,363 shares in the company, valued at $921,817.34. This trade represents a 229.20% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 21,847 shares of company stock worth $1,361,355 over the last quarter. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

GEHC has been the topic of a number of research analyst reports. BTIG Research reduced their target price on GE HealthCare Technologies from $85.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. HSBC cut their price target on GE HealthCare Technologies from $100.00 to $90.00 in a report on Thursday, April 30th. The Goldman Sachs Group reissued a “neutral” rating on shares of GE HealthCare Technologies in a report on Monday. Argus cut their price target on GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Finally, Rothschild & Co Redburn cut their price target on GE HealthCare Technologies from $110.00 to $98.00 in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $80.21.

GE HealthCare Technologies Stock Up 1.0%

GEHC opened at $65.18 on Friday. GE HealthCare Technologies Inc. has a 12 month low of $58.75 and a 12 month high of $89.77. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.22 and a quick ratio of 0.95. The stock has a market cap of $29.65 billion, a P/E ratio of 15.59, a P/E/G ratio of 1.45 and a beta of 0.74. The stock’s 50 day moving average price is $66.32 and its 200 day moving average price is $75.20.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08). GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The business had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the prior year, the business earned $1.01 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, research analysts predict that GE HealthCare Technologies Inc. will post 4.89 earnings per share for the current year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.